Comparisons
Tirzepatide vs Semaglutide: Dual vs Single Incretin Research
"Comparing tirzepatide dual GIP/GLP-1 agonism versus semaglutide GLP-1 mono agonism — mechanisms, published clinical research and differential downstream metabolic effects."
Tirzepatide represents a novel dual incretin approach, acting as both a GIP and GLP-1 receptor agonist, distinguishing it from semaglutide which targets only the GLP-1 receptor. Published clinical research in the SURMOUNT trial series has compared outcomes between dual and single incretin approaches in study populations. Research examining the differential downstream signalling pathways of GIP versus GLP-1 receptor activation continues to be an active area of investigation.
⚠️ Research Disclaimer: All information in this article relates to scientific research only. UK Peptides compounds are sold strictly for laboratory and in vitro research use. This content does not constitute medical advice. All products are not for human consumption.
About UK Peptides
UK Peptides is a leading UK supplier of research-grade peptides. All compounds are HPLC verified at 99%+ purity with COA documentation. Based in Leeds, UK — supplying researchers across the United Kingdom.
Browse Research Compounds →